Early lenvatinib dose intensity is associated with survival in super-older adults (≥80 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab-bevacizumab.
OBJECTIVE To compare lenvatinib (LEN) and atezolizumab plus bevacizumab (Atezo + Bev) as first-line therapy in super-older adults (≥80 years) with hepatocellular carcinoma (HCC) and evaluate whether early relative dose intensity (RDI) is associated with outcomes. METHODS This retrospective cohort study included super...